Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.37 |
| ▸ | P2RY10 | O00398 | 8/20 | 0.37 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.37 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382537 | 0.92 | P2RY10 (0.33) | S1PR2S1PR1S1PR3S1PR4P2RY10 | |
| SCHEMBL3384123 | 0.86 | CYP2D6 (0.33) | LAP3P2RY10GPR34GPR174 | |
| SCHEMBL15757364 | 0.80 | GCLC (0.45) | — | |
| SCHEMBL3380549 | 0.77 | S1PR2 (0.46) | S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL3382375 | 0.76 | SLC1A1 (0.33) | P2RY10GPR34GPR174 | |
| SCHEMBL4751449 | 0.75 | CA4 (0.37) | — | |
| SCHEMBL3659563 | 0.75 | CA4 (0.37) | — | |
| SCHEMBL23929241 | 0.74 | LPAR1 (0.43) | P2RY10GPR34GPR174 | |
| SCHEMBL10671206 | 0.74 | CA4 (0.35) | — | |
| Ammonia Solution, Strong SCHEMBL28656082 | 0.74 | CA4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443954-B1 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | SCRIPPS RESEARCH INST (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7399743-B2 | Targeted thrombosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1443954-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | Novartis Pharma GmbH (AT) | 2004-08-11 | — | — | EP | disclosed |
| US-20030194400-A1 | Targeted thrombosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-5863536-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITOR FOR THE TREATMENT OF GLUTAMATE ABNORMALITIES AND ASSOCIATED NERVOUS TISSUE ISCHEMIA IN A ANIMAL AND FOR TREATMENT OF PROSTATE DISEASE | GUILFORD PHARMACEUTICALS INC. (US) | 1999-01-26 | — | — | US | disclosed |